Identification of Phenotypic Factors That Predict Success for Weight Loss and Long-term Weight Maintenance

Sponsor
University of Michigan (Other)
Overall Status
Recruiting
CT.gov ID
NCT02043457
Collaborator
(none)
3,200
1
196
16.3

Study Details

Study Description

Brief Summary

The Investigational Weight Management Clinic now entitled the Weight Management Program at the University of Michigan was created to identify strategies that will result in cost-effective, long term weight management for overweight and obese individuals. The driving hypothesis of the clinic is that the 'one size fits all' philosophy is untenable with a complex disease such as obesity. The clinic will serve as a portal for patients to choose standard clinical care or to explore alternatives from a variety of clinical studies offered through the clinic. These studies will include further investigations into nutrition, the biological basis of weight and weight management and protocols using approved and experimental pharmaceuticals as well as technologies that aid in self-management of weight.

Condition or Disease Intervention/Treatment Phase
  • Other: phenotyping

Study Design

Study Type:
Observational
Anticipated Enrollment :
3200 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Identification of Phenotypic Factors That Predict Success for Weight Loss and Long-term Weight Maintenance
Study Start Date :
Aug 1, 2009
Anticipated Primary Completion Date :
Dec 1, 2025
Anticipated Study Completion Date :
Dec 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Lifestyle intervention

Opt-in intervention to include the following procedures, called 'phenotyping' performed at baseline, after 10-15% weight loss from baseline weight or 6 months (whichever comes first) and at end of 2 years while in weight maintenance: oral glucose tolerance test, mixed meal tolerance test, with fasting leptin, biased and unbiased metabolomic profiling, DNA, RNA, muscle and adipose tissue biopsies: measurement of resting energy expenditure by indirect calorimetry; oxidative capacity (V02 peak/max); body composition by Dual Energy X-ray Absorptiometry (DEXA) or air displacement plethysmograph (Bod Pod); inventories of depression and health related quality of life instruments, measures of impulsivity, measures of hunger and appetite, work performance (including presenteeism and absenteeism) and pain survey.

Other: phenotyping
Other Names:
  • Phentoyping includes:
  • Health related quality of life questionnaires
  • Depression Inventory
  • Work Performance
  • Resting Energy Expenditure measured by indirect calorimetry
  • Oxidative Capacity measured by V02 max
  • Body composition measured by Dual Energy X-ray Absorptiometry (DEXA) or air displacement plethysmograph (Bod Pod)
  • Mixed Meal Tolerance Testing with metabolomic profiling and hormone evaluation
  • Oral Glucose Tolerance Testing
  • DNA
  • RNA
  • Muscle biopsy (from vastus lateralis)
  • Adipose tissue biopsy from abdomen
  • Survey regarding pain
  • Outcome Measures

    Primary Outcome Measures

    1. Phenotypic factors related to weight loss and long-term weight maintenance [Change in phenotypic factors from baseline to 3-6 months and at 2 years]

      Phenotypic factors include: blood glucose levels, lipomic/metabolomic measurements, genetic analysis, body fat percentage, maximal oxygen consumption, respiratory quotient, resting metabolic rate, physical/emotional health

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    15 Years to 75 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Obese males and females: age >20 years; Obese population defined as BMI > or = 27 kg/m2

    • Lean population BMI < 27 but > 17 kg/m2

    • Able and willing to provide written informed consent for the trial

    Exclusion Criteria:
    • Evidence of inherited disorders of lipid metabolism.

    • History of Cancer within the last 5 years

    • Human immunodeficiency virus (HIV) antibody positive.

    • Patients with solid organ transplants.

    • Participation in any other clinical trial within 90 days of entry into this trial.

    • Pregnant or lactating females.

    • Uncontrolled thyroid disease

    • Unstable angina or NY heart association class II failure or above

    • Gastrointestinal disease specifically GI motility disorders

    • Unstable neuropsychiatric disease including major depression/anxiety, eating disorder such as binge eating, bulimia or anorexia

    • End stage renal or hepatic disease

    • Autoimmune disorders (e.g. SLE)

    • Body weight fluctuation of more than 5 kg in the previous 3 months

    • Prior bariatric surgery

    • A history or current alcohol/substance abuse and change in smoking habits or cessation in the past 6 months.

    • Women of childbearing age must use a reliable form of contraception.

    • Any medical condition, which in the opinion of the investigator would make the patient unsuitable for recruitment, or could interfere with the patient participating in or completing the protocol.

    • Unwilling or unable to consent for the study.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Michigan Ann Arbor Michigan United States 48106

    Sponsors and Collaborators

    • University of Michigan

    Investigators

    • Study Director: Charles Burant, MD, PhD, University of Michigan

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    Amy E Rothberg, Professor of Internal Medicine, University of Michigan
    ClinicalTrials.gov Identifier:
    NCT02043457
    Other Study ID Numbers:
    • HUM00030088
    First Posted:
    Jan 23, 2014
    Last Update Posted:
    Aug 23, 2022
    Last Verified:
    Aug 1, 2022
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 23, 2022